Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04871451
Other study ID # ABP-19002
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 27, 2021
Est. completion date July 24, 2023

Study information

Verified date December 2023
Source AEON Biopharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Open-label Extension trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 42 sites in the United States from Phase 2 (ABP-19000) and Phase 3 (ABP-19001) trials and 29 sites in Europe from Phase 3 (ABP-19001) trial. Study subjects who had their initial dose of study drug in Phase 2 or Phase 3 trial studies, irrespective of treatment allocation, will be eligible to enroll in this OLE study.


Description:

This Open-label Extension trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 42 sites in the United States from Phase 2 (ABP-19000) and Phase 3 (ABP-19001) trials and 29 sites in Europe from Phase 3 (ABP-19001) trial. Study subjects who had their initial dose of study drug in Phase 2 or Phase 3 trial studies, irrespective of treatment allocation, will be eligible to enroll in this OLE study. Study subjects will receive a predetermined dose of ABP-450 between the Low Dose and High Dose, based on the investigator's discretion and clinical judgment.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date July 24, 2023
Est. primary completion date July 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Qualified for and had their initial dose of study drug in the ABP-19000 or ABP-19001 studies and for whom 8 weeks have elapsed between last treatment in the double-blind study (ie, EOS visit) and first treatment in the ABP-19002 OLE study. 2. Provided written informed consent to being treated for cervical dystonia with ABP-450. 3. Were a male or female patient between 18 and 75 years of age (inclusive) when they entered the ABP-19000 or ABP-19001 studies. 4. Have clinical diagnosis of cervical dystonia and need for injection, as determined by the investigator, with TWSTRS total score =20. 5. Entered the ABP-19000 or ABP-19001 study on a stable dose of medications (if any) used for focal dystonia treatment (eg, anticholinergics and benzodiazepines) for =3months prior to and expected throughout the duration of the study. 6. Stated willingness to comply with all study procedures, including attendance at the study center for all study visits as scheduled and have technological capabilities to have tele visits. Exclusion Criteria: 1. Have traumatic torticollis or tardive torticollis. 2. Have predominant retrocollis or anterocollis. 3. Have hypersensitivity to human serum albumin, sucrose, or botulinum toxin type A. 4. Have diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease that might interfere with the study. 5. Have marked limitation on passive range of motion that suggests contractures or other structural abnormality (eg, cervical contractures or cervical spine syndrome). 6. Have medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. 7. Current swallowing disorder of any origin (dysphagia scale =3, ie, severe, with swallowing difficulties and requiring a change in diet). 8. Participated in another interventional study during participation in this study. 9. Were a pregnant or lactating female, or female of child-bearing potential not willing to use an acceptable method of contraception (ie, intrauterine device, barrier methods with spermicide, or abstinence). 10. Would not benefit from treatment with ABP-450 for their cervical dystonia, in the investigator's opinion. 11. Viral or other active infection or any medical condition that, in the opinion of the investigator, classifies the patient as unsuitable for participation in the study or patients who do not seem to be in good general health at the time of Day 0 "rollover", and prior to any investigational study drug administration.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States Emory University Atlanta Georgia
United States Rush University Medical Center Chicago Illinois
United States Cleveland Clinic Lou Ruvo Center for Brain Health Cleveland Ohio
United States The Cleveland Clinic Foundation Cleveland Ohio
United States Michigan State University East Lansing Michigan
United States Quest Research Institute - Hunt - PPDS Farmington Hills Michigan
United States Parkinson's and Movement Disorder Institute Fountain Valley California
United States Neuro Pain Medical Center Fresno California
United States Infinity Clinical Research LLC Hollywood Florida
United States Baylor College of Medicine Houston Texas
United States Loma Linda University Loma Linda California
United States Veracity Neuroscience LLC Memphis Tennessee
United States Brainstorm Research Miami Florida
United States Vanderbilt University Medical Center Nashville Tennessee
United States The Orthopedic Foundation New Albany Ohio
United States Arizona Neuroscience Research Phoenix Arizona
United States New England Institute for Neurology and Headache Stamford Connecticut
United States University of South Florida Tampa Florida
United States Neurology One Winter Park Florida

Sponsors (2)

Lead Sponsor Collaborator
AEON Biopharma, Inc. PPD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-related Serious Adverse Events The primary safety endpoint will be the incidence of treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with ABP-450 between Low Dose and High Dose. Up to 52 weeks
Secondary Mean Change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score The mean change in the total score of the TWSTRS since the start of treatment will be assessed by treatment group. The TWSTRS total score is a summation of the following subscales: Severity scale, Disability scale and Pain scale of 0 - 85 with a higher score representing a worse outcome.
with a higher score representing a worse outcome.
Up to 52 weeks
Secondary Mean Change in the subscale score of severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) The mean change in the subscale score of severity of the TWSTRS since the start of treatment will be assessed by Treatment Group. This subscale has a scale of 0 - 35 with the higher score representing the greater severity. Up to 52 weeks
Secondary Mean Change in the subscale score of disability of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Spasmodic Torticollis Rating Scale (TWSTRS) The mean change in the subscale score of disability of the TWSTRS since the start of treatment will be assessed by Treatment Group. This subscale has a scale of 0 - 30 with the higher score represents the greater disability. Up to 52 weeks
Secondary Mean Change in the subscale score of pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) The mean change in the subscale score of pain of the TWSTRS since the start of treatment will be assessed by Treatment Group. This subscale has a scale of 0 - 20 with the higher score represents the greater disability. Up to 52 weeks
Secondary Mean Change in Patient Global Impression of Change (PGI-C) The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale with a 1-item scale ranging from "much better" to "much worse" with the higher score indicating worsening of symptoms will be assessed by Treatment Group. Up to 52 weeks
Secondary Mean Change in Patient Global Impression of Severity (PGI-S) The mean change in the subject's assessment of the severity of their condition since the start of treatment measured by the Patients' Global Impression of Severity (PGI-S) Scale with a 1-item scale ranging from "normal" to "severely ill" with the higher score indicating greater severity in illness will be assessed by Treatment Group. Up to 52 weeks
Secondary Mean Change in Clinical Global Impression of Change (CGI-C) The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score will be assessed by Treatment Group. CGI-C is a clinical assessment with a 7-point scale ranging from "very much improved" to "very much worse". Up to 52 weeks
Secondary Mean Change in Clinical Global Impression of Severity (CGI-S) The mean change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score will be assessed by Treatment Group. CGI-S is a clinical assessment of the patient's illness severity on a 7-point scale ranging from "normal" to "among the most extremely ill patients". Up to 52 weeks
Secondary Time from the First ABP-450 Dose to the First Visit Without Efficacy The time from first ABP-450 dose to the first visit (from Week 2) without efficacy with regards to TWSTRS total score =20 will be captured. Up to 12 Weeks
See also
  Status Clinical Trial Phase
Completed NCT03617367 - Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) Phase 3
Not yet recruiting NCT04057911 - A Trial of Non-invasive Stimulation in Cervical Dystonia N/A
Withdrawn NCT02180139 - tDCS in Cervical Dystonia N/A
Completed NCT00541905 - Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia Phase 4
Unknown status NCT00418925 - Efficacy of Dronabinol for the Treatment of Cervical Dystonia Phase 2
Not yet recruiting NCT05715138 - Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia N/A
Completed NCT02959645 - Assessment of Brain Activities in Cervical Dystonia
Completed NCT02131467 - Safety and Tolerability of Perampanel in Cervical Dystonia Phase 1/Phase 2
Completed NCT03805152 - Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia Phase 3
Completed NCT04949594 - Relief of Pain in Patients With Cervical Dystonia Through the Use of Transcutaneous Electric Nerve Stimulation (TENS)
Recruiting NCT01664013 - The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Phase 4
Completed NCT00447772 - Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Phase 3
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT05157100 - Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia Phase 4
Completed NCT00257660 - Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Phase 3
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Terminated NCT00760318 - Keppra for Cervical Dystonia Phase 2
Completed NCT00323765 - Plasticity in Cervical Dystonia N/A
Completed NCT04171258 - Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia Phase 1
Completed NCT04849988 - A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia Phase 2